OTC : GIFOF

Grifols, S.A.

$8.85 USD

$0 (0.0%)

Volume
149
Average Volume
633
Market Capitalization
$8.7B
P/E Ratio
15.60
Dividend Yield
0.87%
Price Target
Year High
$8.85
Year Low
$8.20
Day High
—
Day Low
—
Payout Ratio
$0.31
Current Ratio
$2.47
Company Overview

OTC

Jose Ignacio Abia Buenache

Drug Manufacturers - General

Healthcare

GIFOF

23833

ES

USD

https://www.grifols.com

34 93 571 02 21

N/A

0001438569

Liquidity Metrics

1.77

2.47

0.85

0.33

0.31

Sales & Valuation

$7.52B

0.87

1.19

8.59

1.11

Profitability

$0.59

$401.74M

5.58%

8.23%

7.88%

2.07%

P/E Metrics

15.60

0.13

0.13

Analyst Price Target & Rating

Neutral

3/5

7 Analysts

%

Financial Health Scores

1.11

5/9

$3.14B

$20.15B

$12.28B

$1.08B

Key Metrics (TTM)

$15.38B

2.07

10.73

2.47

7.88%

5.49%

6.48%

11.76%

$10.49

319 days

Company Executives
Name Title
Ignacio Ramal Subira Chief Internal Audit & Enterprise Risk Manager
Vicente Blanquer Torre Chief Quality Officer
Lluis Pons Gomez Senior Vice President of Strategy & Chief Operating Officer Office
Sergio Roura Adell President of Commercial Tech Support
Daniel Fleta Coit Chief Industrial Services Officer
Montse Ribas Chief Communications and Reputation Officer
Daniel Segarra Head of Investor Relations & Sustainability and Vice President
Camille Alpi Chief Human Resources & Talent Officer
David Ian Bell Chief Corporate Affairs & Legal Officer
Enrique de la Torre Chief Compliance Officer
Jose Ignacio Abia Buenache Chief Executive Officer & Director
Rahul Srinivasan Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Grifols, S.A. (OTC:GIFOF) Stock

Grifols, S.A. is a Barcelona, Spain-based pharmaceutical company founded in 1940. The company primarily specializes in the acquisition, production, and distribution of therapeutic solutions, with a significant emphasis on products derived from human plasma. Its operations are divided into several key business units: The Bioscience division is dedicated to the research, development, manufacturing, and commercialization of plasma-based medicines and other cutting-edge therapies. These are designed to treat patients suffering from chronic, rare, prevalent, and life-threatening conditions. Their product portfolio includes immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies non-biological pharmaceutical items, medical consum ... ables, clinical nutrition products, intravenous treatments, and various medical devices to healthcare facilities. The Diagnostic division focuses on innovating, producing, and bringing to market diagnostic tools. These tools support the entire healthcare process, from disease prevention and initial screening to definitive diagnosis, prognosis, and ongoing treatment monitoring for medical professionals. The Bio Supplies division provides essential biological materials used in life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic goods. Grifols' diverse range of products and services are utilized by healthcare providers worldwide for diagnosing and treating a variety of medical conditions, including hemophilia, immune system disorders, and infectious diseases. The company caters to a wide customer base that includes both public and private sector clients, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. Furthermore, Grifols, S.A. maintains a technological collaboration agreement with Mondragon.

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

2026-07-03 10:49:07

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

2026-06-15 08:00:00

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

2026-05-09 15:31:13

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Grifols, S.A. (GIFOF) stock price?

Grifols, S.A.(OTC:GIFOF) stock price is $8.85 in the last trading session. During the trading session, GIFOF stock reached the peak price of $8.85 while $8.2 was the lowest point it dropped to. The percentage change in GIFOF stock occurred in the recent session was 0.0% while the dollar amount for the price change in GIFOF stock was $0.

GIFOF's industry and sector of operation?

The OTC listed GIFOF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of GIFOF?

Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager
Vicente Blanquer Torre | Chief Quality Officer
Lluis Pons Gomez | Senior Vice President of Strategy & Chief Operating Officer Office
Sergio Roura Adell | President of Commercial Tech Support
Daniel Fleta Coit | Chief Industrial Services Officer

How many employees does GIFOF have?

Number of GIFOF employees currently stands at 23833. GIFOF operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

Link for GIFOF official website?

Official Website of GIFOF is: https://www.grifols.com

How do I contact GIFOF?

GIFOF could be contacted at phone #34 93 571 02 21 and can also be accessed through its website. GIFOF operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

How many shares of GIFOF are traded daily?

The average number of GIFOF shares traded daily for last 3 months was 633.

What is the market cap of GIFOF currently?

The market value of GIFOF currently stands at $8.7B with its latest stock price at $8.85